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Mitochondrial diseases are a clinically diverse group of genetic disorders that often present to neurologists. Health related quality of
life (HRQOL) is increasingly recognised as a fundamental patient based outcome measure in both clinical intervention and research.
Generic outcome measures have been extensively validated to assess HRQOL across populations and different disease states.
However, due to their inclusive construct, it is acknowledged that not all relevant aspects of a specific illness may be captured. Hence
there is a need to develop disease specific HRQOL measures that centre on symptoms characteristic of a specific disease or condition
and their impact. This study presents the initial conceptualisation, development and preliminary psychometric assessment (validity
and reliability) of a mitochondrial disease specific HRQOL measure (Newcastle Mitochondrial Quality of life measure (NMQ)).
NMQ is a valuable assessment tool and consists of 63 items within 16 unidimensional domains, each demonstrating good internal
reliability (Cronbach’s aP 0.83) and construct validity.
 2013 Elsevier B.V.
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Mitochondrial disorders are a clinically multifarious
group of genetic disorders that affect the central nervous
system and skeletal muscles and other organs heavily
dependent on aerobic metabolism. They are typically
characterised by multi-system involvement. They have
extensive phenotypic and disease burden variability and
although a disease rating scale [1] exists which monitors0960-8966  2013 Elsevier B.V.
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Open access under CC BY license.the spectrum and rate of progression of disease, it does
not assess the psychological and social impact of having
a mitochondrial disorder.
Health related quality of life (HRQOL) is increasingly
recognised as a fundamental patient-based outcome
measure in both clinical intervention and research.
Generic outcome measures have been extensively
validated to assess HRQOL across populations and
different disease states. However due to their inherent
generic construct they may not fully capture all relevant
aspects of a specific illness [2]. It is recognised that there
is a need to develop disease-specific HRQOL measures
that centre on the symptoms and impact characteristic of
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conceptualisation, development and preliminary
psychometric evaluation (validity and reliability) of a
mitochondrial disease-specific HRQOL measure.
2. Methods
2.1. Subjects and source of items
Eligible participants were defined as adult patients
(18 years and above) with a known biochemical or
genetic diagnosis of mitochondrial disease. Subjects were
excluded if they had cognitive impairment that prevented
questionnaire comprehension or were unable to read
English.
Domain and item content validity of the pilot
questionnaire was assured by deriving item content
through semi-structured key-informant interviews.
Investigators conducted two focus groups to explore
patients’ perceptions of the physical, psychological and
social impact of mitochondrial disease through open
questions and the employment of the ‘Gap Model’
technique [4]. Themes which were perceived as influential
on HRQOL in mitochondrial disease and arose during
the interview processes or from review of other
neurological and HRQOL instruments [5–8] were
categorised into representative life domains as verified
independently by three investigators.
2.2. Questionnaire design
Questionnaire design was determined by reference to
questionnaire design guidelines and by advice from a
survey methods consultant. A four week recall period
and an adjective rating scale (never, occasionally,
sometimes, often, always, not applicable) were selected as
the most appropriate recall time-frame and response scale
respectively. To test basic comprehension and
acceptability, and prior formal piloting, a first draft
questionnaire was piloted on randomly selected patients
with mitochondrial disease. Relevant changes were made.
2.3. Item reduction and validation
Patients attending the Newcastle mitochondrial disease
clinic were asked to complete the pilot questionnaire to
(1) confirm that the items and domains selected from the
interviews and review of other HRQOL instruments were
representative; (2) to highlight any issues that may have
been omitted; (3) to facilitate item reduction. Preliminary
data were evaluated to assess endorsement rate, scale
reliability and variability. With the use of five criteria,
both item and domain contributions to the scale were
evaluated. Domains were assessed by prespecified criteria
[9]: (1) Items as a whole were evaluated using frequency
of endorsement. Those with very high (>80%) or low
(<20%) endorsement rates, of any one category, wereremoved as such items are unlikely to be sufficiently
discriminatory. (2) Domain variability was assessed using
factor analysis. An Eigen value cut off point of 0.95 was
used, as it was a requirement that each domain would be
unidimensional. Any items within a domain with a
cumulative Eigen value >0.95 were eliminated. (3) To test
the internal reliability of each item within a domain,
item-total correlations were calculated; an item-total
correlation of greater than 0.20 were accepted as
indicative of adequate internal reliability; items with
item-total correlation of 60.20 were eliminated. (4) Items
were removed where the Cronbach’s a for the constituent
domain was greater if that item was removed than if the
item was retained. (5) Domains with a Cronbach’s a
<0.70 or >0.95 were dropped. Once redundant items were
removed face to face cognitive interviews were conducted
to verify comprehension and ensure face validity.
2.4. Psychometric evaluation
The amended questionnaire (NMQ: Newcastle
Mitochondrial-Quality of life measure) was piloted again
to facilitate further content validity and psychometric
evaluation. Subjects were asked to complete NMQ and a
validated HRQOL measure (SF-36) [10]. Data were
evaluated to assess endorsement rate and scale reliability
(internal consistency reliability) and variability. Construct
validity was assessed by comparing questionnaire
responses to comparable elements of the SF-36. Multi-trait
analysis was used to examine correlations within and
across similar and dissimilar domains in each instrument;
we anticipated that scales measuring similar constructs
(for example, Role physical (SF-36) and mobility
(NMQ)) would be more highly correlated with one
another than those tapping dissimilar constructs. Known
group validity was established using the Newcastle
Mitochondrial Disease Adult Scale (NMDAS) [1], a
validated measure of disease burden and a surrogate for
phenotypic severity, with one-way analysis of variance
performed. Subjects were divided into 3 groups according
to their NMDAS scores (Group 1: 0–24 (mild); Group 2:
25–49 (moderate); Group 3: 50 and above (severe))
disease burden. This allowed the assessment of how well
the questionnaire was able to distinguish changes in
quality of life in relation to disease severity. It was
expected that there would be a negative relationship
between NMQ and NMDAS scores, that is, the greater
the disease burden, the poorer the perceived quality of
life, reflected in lower NMQ scores.
2.5. Scoring methods
The raw score (obtained by adding across all items in the
domain) for each NMQ domain (Never: 5; rarely: 4,
sometimes: 3, often: 2 and always: 1) was transformed to
a 0–100 score, as in the calculation of subscale scores for
the SF-36, by the following formula
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 the number of items=½maximum possible
minimum possible score per domain  1002.6. Statistical analysis
All statistical analyses were performed using Minitab
version 17.
3. Results
3.1. Item generation, reduction and validation
Derivation of NMQ is summarised in Fig. 1. Nine
patients (5 men; mean age 41 years (SD 17 years))
attended the semi-structured key-informant interviews.
Six randomly selected patients with mitochondrial disease
(3 men; age range 28–56 years) completed the first draft
questionnaire. From this, a pilot questionnaire consisting
of 19 domains (103 items) as determined by the research
team covering all themes mentioned during patient
interviews and named according to their constituent
items, was generated (Fig. e-1). One hundred and sixty
patients were invited to complete the pilot questionnaire;
131 were returned (response rate of 81.9%).Quantitative: Psychometric Validation
Construct validity; multi-trait analysis
(SF36)
Known group validity; one-way analysis of variance 
(NMDAS)
NMQ (63 items)132/ 219 completed
Qualitative: Item Reduction
Endorsement rates (items as a whole); Domain 
variability (frequency of endorsement); Item total 
correlations (Cronbach’s α) (40 items including 
3 domains removed)
19 face to face interviews/Debriefing method/ Change of 
response reply/ Change of questionnaire design
Pilot questionnaire (103 items)
131/160 completed
Qualitative: Item Generation
Literature review/key informant interviews/ focus 
groups (n=9)
General interpretability/ content validity/ scaling 
responses
Fig. 1. Summary flow chart of the steps involved in the derivation of
NMQ.Face to face cognitive interviews were conducted to
check on face and content validity and how
understandable the items were. Nineteen patients were
interviewed (8 men; mean age 41 years (SD 14 years)).
Amongst the issues raised and subsequently addressed
were: (1) font size was increased to 14 for ease of
readability; reflecting how visual problems are common
in mitochondrial cytopathies (2) the response scale was
adjusted: ‘not applicable’ was omitted; and ‘occasionally’
was changed to ‘rarely’. (3) Questionnaire layout was
changed to incorporate a colour–contrast background
with individual response boxes and clearer instructions
for ease of completion. Factor analysis showed that all
domains were unidimensional, that is, measured one
aspect of disease in both the pilot and final NMQ
questionnaires. The internal reliability of retained
domains remained high in all domains (Cronbach’s a
>0.83) (Table 1). Item and domain contributions to the
scale, according to the pre-specified criteria were also
evaluated. These processes resulted in the removal of 40
items, including 3 whole domains: stroke, seizures and
work due to low endorsement (Fig. e-2a and b),
cumulative Eigen values >0.95 (Table e-1) and/or
Cronbach’s a >0.95 (Table 1), as well as the category of
‘not applicable’ from the response scale. The final
questionnaire (NMQ) consisted of 63 items within 16
unidimensional domains (Fig. e-3).3.2. Psychometric evaluation – construct and group validity
Two hundred and nineteen patients were asked to
complete NMQ and SF-36; 132 were returned (responseTable 1
A summary of the internal reliability of domains within the initial draft
and final version of the mitochondrial disease specific quality of life
questionnaire (NMQ) as assessed by Cronbach’s a demonstrating good
internal reliability.













Mobility 6 0.78 5 0.91
Activities of daily
living
6 0.92 4 0.88
Vision 3 0.74 2 0.83
Memory 1 N/A 1 N/A
Pain 4 0.90 4 0.91
Migraine 4 0.82 3 0.89
Emotion 8 0.94 3 0.88
Stigma 6 0.92 3 0.88
Family role 4 0.90 4 0.87
Personal
relationships
6 0.76 6 0.84
Social role 4 0.92 3 0.92
Diabetes 8 0.92 5 0.93
Stroke 5 1.0 N/A N/A
Seizures 8 0.97 N/A N/A
Work 3 0.94 N/A N/A
N/A: not applicable.
Table 3
Known group validity analysis of NMQ domains as assessed by one-way
analysis of variance showing that as disease severity increases, and NMQ
domain scores decrease in all domains except stigma, emotional well-being
and diabetes.
NMQ domains F p
Activities of daily living 21.02 0.0005
Mobility 21.63 0.0005




Food and digestion 5.17 0.007
Pain 13.23 0.0005
Muscle stiffness 11.28 0.0005
Migraine/headaches 7.31 0.001
Emotional well being 2.77 0.067
Stigma 1.15 0.319
Family role 5.10 0.007
Personal relationships 5.46 0.0005
Social role/support 15.88 0.0005
Diabetes 0.38 0.686
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53 years, SD 14) and 41 men (mean age 48, SD 16).
Sixty-three respondents had a diagnosed point mutation
(m.3243A>G MELAS mutation (mitochondrial
encephalopathy, lactic acidosis and stroke-like episodes)
(39); m.8344A>G MERRF mutation (myoclonic epilepsy
with ragged red fibres) (9); LHON (Leber’s hereditary
optic neuropathy) (2) NARP (neuropathy, ataxia and
retinitis pigmentosa) (1); other mitochondrial tRNA
(mt-tRNA) mutations (12). Forty-three participants were
diagnosed with multiple mtDNA deletions (unspecified
nuclear genetic defect (26), OPA1 (optic atrophy type 1)
(3), POLG1 (polymerase gamma) (6) and PEO1 (Twinkle)
(8)). Twenty-six participants were diagnosed with
heteroplasmic single-large scale mtDNA deletion. Salient
clinical features of respondents as a whole are summarised
in Table e-2. With respects to the m.3243A>G point
mutation group, 13 patients had a history of current or
remote seizures and strokes, 14 subjects had either a
classical maternally inherited diabetes and deafness
(MIDD) or isolated sensori neural hearing loss (SNHL)
phenotype, 10 had a pure myopathic phenotype and 2
respondents were asymptomatic carriers.
NMQ domains correlated with related SF-36 domains
confirming good construct validity (Table 2). There were
no comparable domains for vision, food and digestion,
memory and diabetes. No systematic differences in NMQ
domain scores were found with respect to age (Pearson’s
product-moment correlation co-efficient), gender
(independent-samples t-test) or genotype (One-way
analysis of variance) (Table e-3). Known group validity
analysis revealed that NMQ subscale scores varied with
disease severity in all domains except emotional well
being, stigma and diabetes (Table 3).Table 2
A summary of the construct validity of NMQ domains compared to
equivalent SF-36 domains as assessed by Pearson’s correlation co-efficient
showing good construct validity.
NMQ domains SF-36 domain










Family role 0.24 0.36 0.24
PR 0.73 0.24 0.20
Social role 0.29 0.30 0.25
PF = physical function; RP = role physical; VT = vitality; SF = social
function; BP = bodily pain; RE: role emotion; MH = mental health;
PR = personal relationships.
Italics denotes moderate correlation (Pearson’s product moment
correlation co-efficient (r = 0.3–0.69); Bold denotes strong correlation
(r > 0.7).4. Discussion
Mitochondrial disease can have a significant impact on
patients’ quality of life. The high response rates of both
pilot and NMQ questionnaires provide evidence that
patients with mitochondrial disease welcomed the
opportunity to report on their quality of life. The
breadth of themes volunteered by patients during NMQ
derivation reflects the large spectrum of symptoms in
patients with mitochondrial disease and their wide-ranging
influence on many aspects of functional and mental
health and well being.
HRQOL is important for understanding the impact and
progression of chronic disease. Indeed, in a condition were
the natural history of the disease is poorly understood and
therapeutic options are limited, long-term preservation of
HRQOL in mitochondrial disease poses a real challenge.
SF-36 and its abbreviated version SF-12 are currently
the only tools used routinely for measuring patient-reported
outcomes in our patients with mitochondrial disease.
Stroke, seizures and work domains of the initial
pilot questionnaire did not show adequate construct
validity or internal consistency reliability and were
excluded from NMQ. Criticism in the past has been that
the structure and content of HRQOL measures do not
capture all of the issues relevant to the patient and often
do not allow them to indicate the impact of disease
burden on their perceived QOL. We endeavoured, at all
stages of the construct of NMQ to correct this
shortcoming during its conceptualisation and validation.
Although our initial bias was to include domains that we
felt from a physician-centred perspective were relevant to
patient’s quality of life such as stroke and seizures;
repeatedly these aspects were not considered important to
this patient group as a whole. This may reflect the low
prevalence of strokes (12%) and seizures (14%) within our
328 J.L. Elson et al. / Neuromuscular Disorders 23 (2013) 324–329cohort and the genotypic-phenotypic specificity of such
symptoms. However, this may also suggest that the
domain items included in the original pilot questionnaire
lacked ability to discriminate the impact of seizures and
stroke on perceived quality of life within the affected
group of patients.
In an attempt to address two of the shortcomings of the
SF-36, NMQ includes domains of cognitive functioning
(memory/cognition) and sexual functioning (personal
relationships). Cognitive function domain originally
consisted of four items and was reduced to one by
combining two items (‘found it difficult to make
decisions’ and ‘have you felt your thinking is confused’)
for ease of completion. Two further items (‘had problems
with memory’ and ‘had problems with your
concentration’) were omitted due to repeatedly low
endorsement rates. No amendments were made to the
personal relationships domain; the key-informant
interviewees highlighted this domain as an important
quality of life measure not routinely assessed; which the
group as a whole endorses. Impact of mitochondrial
disease on work and employment are addressed within
several subscales. Other life domains encompassed in
NMQ but not SF-36 includes vision, memory, food and
digestion and diabetes. Within specific domains, other
items not routinely assessed in generic HRQOL and
pertinent to patients’ with mitochondrial disease have
been addressed such as hearing loss (communication
domain) which is recognised to be prevalent in
mitochondrial disease.
Completion of NMQ is simple and quick (on average
3–5 min) and scoring of the questionnaire is similar to that
of the SF-36. Each domain is transformed into a 0–100
scale on the assumption that each question carries equal
weight, thus the higher the percentage NMQ domain score
the greater the perceived quality of life and health status.
The psychometric evaluation of NMQ provides good
evidence of both reliability and validity. Internal
consistency of each of the domains exceeded the 0.7
threshold and item-total correlations exceeded 0.2 for all
items. NMQ domain scores of mobility, muscle stiffness,
emotion, family role and social role show moderate to
strong correlation between similar SF-36 domains (r
values 0.3–0.69), with the strongest correlation occurring
with NMQ personal relationships’ domain and SF-36
role physical domain. NMQ domains of activities of daily
living, energy, communication, pain, migraine and stigma
show poor correlation with their comparative SF-36
health concepts. These domains remained within NMQ
as they were considered important by our patient
interview group and investigators during content validity
assessment. We acknowledge that NMQ and SF-36
domain pairing for statistical analyses may not have been
ideal, for example, migraine and body pain, and
communication and social functioning but it is also
recognised that internal consistency is affected by the
degree of item correlation and the number of itemswithin a domain with considerable variation between
NMQ and SF-36 domain item content noted.
These findings are encouraging with further
psychometric assessment and revision of NMQ required
particularly in relation to the domains of stroke and
seizures. Test-retest reliability and responsiveness to
change will be undertaken in the future. This maybe best
facilitated by a European multi-centre follow-up analysis.
With little known about progression of mitochondrial
disease, assessing HRQOL may contribute to our
understanding of disease impact and evolution over time.
Indeed, if HRQOL is a true marker of disease burden
and better reflects functional status and well-being than
traditional biological outcome measures, then it is
imperative that we have a validated disease-specific tool
which will facilitate longitudinal time-based monitoring
in research and clinical practise.Disclaimers
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